MDxHealth, a developer of epigenetic tests for cancer assessment, has introduced ConfirmMDx assay to detect prostate cancer.

ConfirmMDx test is designed to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer.

The test detects an epigenetic field effect or ‘halo’ associated with the cancerization process at the DNA level in cells adjacent to cancer foci, thus facilitating urologists to identify men who may undergo unnecessary repeat biopsies.

MDxHealth CEO Jan Groen said, "MDxHealth is uniquely positioned with its portfolio of epigenetic assays to capitalize on the realization of true personalized medicine, improving patient care, while reducing healthcare costs."

The company is applying patented DNA methylation platform and biomarkers to address growing unmet medical need for better cancer diagnosis and treatment information.